Compliance initiatives

Based on the mission statement in its management philosophy of "contributing to society by creating and offering superior pharmaceuticals and health-related products as well as healthcare-related information and services in socially responsible ways that enrich people's lives by improving health and beauty," Taisho Pharmaceutical has been endeavoring to develop its business activities sincerely and earnestly by valuing the idea of "corporate activities as shinsho*, its founding spirit.

The Company is committed to compliance as a company-wide initiative so that all employees will understand this idea correctly and each of them is always able to practice it in his or her duties.

*This refers to operating a business with honesty, diligence, and passion; instilling an individual and a company with pride to fairly interact with society and consumers.

Code of Conduct and Declaration of Corporate Conduct

In 2001, Taisho Pharmaceutical formulated its Code of Conduct as its standard of judgment when working to achieve its corporate mission and as basic guidelines for conduct at various workplaces to realize our corporate mission. In addition, we work to instill thorough understanding of the code by providing each employee with a copy of the Compliance Guide, which concretely explains each item in the code.

Since 2006, to enable more immediate and specific understanding of the code, we have been formulating a code of conduct for each division. Divisions are using their codes as guidelines in the context of actual situations, and these codes are reviewed as needed due to changes in the business environment and organization. In 2010, in light of changes in society, we formulated the Declaration of Corporate Conduct and announced it inside and outside the Group. In 2014, we distributed the Compliance Guide Booklet to further promote understanding and practical application of compliance in the workplace.

In 2018, we formulated our Global Compliance Guideline with the aim of establishing even stronger management foundations to ensure that we continue to achieve steady growth and development amid global competition. We strive to implement proper compliance in the course of daily activities while respecting cultural diversity.

Compliance with Laws and Social Standards in Each Country

We will comply with laws, ordinances, regulations, social standards, business practices and internal rules, and clarify our commitment to understand and respect the purpose and objectives underlying these principles in our Global Compliance Guideline, making these known to all employees.

Compliance with Social Standards and Commitment to Corruption Prevention

  • As a company engaged in the development, manufacture and sale of pharmaceuticals that foster the wellbeing of people, we work earnestly to respect the sanctity of life and promote a commonsense view of pharmaceuticals.
  • We continuously collect information concerning the safety of our products in accordance with the relevant laws and regulations in each country and appropriately report the findings to the pertinent authorities as required.
  • Particular care is taken to maintain a proper relationship with government officials and medical professionals. We never engage in dealings such as providing illegal payments to the public servants, foreign civil servants or other parties of any country.
  • We exercise constant vigilance to legal and social practices, never ignore unlawful or antisocial acts, always behave in a sensible manner, and reject the demands from antisocial influences or groups involved in activities that may threaten the order and safety of civil society.

Prevention of Bribery

We do not provide special preferences to certain customers and business partners or abuse our dominant bargaining position, and we comply with applicable laws and regulations and secure contracts and engage in business transactions in an appropriate manner. We prohibit any business transaction deemed to be collusion with a customer or business partner.

We do not provide money or entertainment that may lead to an improper relationship or an impression of bribery and prohibit activities such as providing conveniences or requesting a customer or business partner to provide money, entertainment or other conveniences by taking advantage of their own position or relationships. Such convictions are detailed in the Global Compliance Guideline and made known to employees in both Japan and overseas.

Respect of Human Rights

We clarify in the Global Compliance Guideline our stance toward respect of human rights and individuality as well as elimination of improper behavior that could infringe an individual’s dignity (harassment) or lead to discrimination, and make this known to all employees.

In addition to eliminating discrimination based on gender, nationality, race, religion, age, belief, physical disabilities or other such factor, we are committed to avoiding acts that cause discomfort to others even though discrimination may not be intended. We also strive to eliminate forced labor, child labor and other forms of slave-type treatment.

Compliance Framework

To ensure that our compliance efforts progress steadily in Japan and at our overseas subsidiaries, the officers of Taisho Pharmaceutical Holdings are compliance officers and the company's Internal Affairs Department specializes in this commitment to compliance.

All officers assist the compliance officer, and are responsible for compliance education in their respective divisions. General managers and group managers promote monitoring and education activities in their divisions and groups to ensure thorough compliance. Generally, two members of each division are in charge of compliance matters within their division. They assist the general manager in promulgating compliance and handle workplace monitoring and consultations with employees.

In addition, as our basic structure for carrying out compliance, we emphasize implementing process management using a Plan-Do-Check-Action management cycle to achieve our targets.

Moreover, we work to educate the employees of major subsidiaries, including those overseas, regarding compliance in daily activities with social standards (including laws, social norms and corporate ethics) our philosophy, Declaration of Corporate Conduct, Code of Conduct and internal rules.

In this manner, we create a Groupwide compliance mindset by broadly promoting compliance activities that are rooted in the workplace. We have also established a framework for quickly detecting compliance issues and discussing questions so that the entire Group can take a proactive approach to compliance.


Taisho Pharmaceutical Holdings has established wide-ranging hotlines for reporting, consultation and fielding concerns regarding actions such as corporate or individual violations of laws, ethics or internal rules based on the Company’s Internal Reporting Regulations. These include the Compliance Management Section Hotline, the Harassment Hotline, an external hotline known as the External Attorney Hotline, and the Counselor Section Hotline. Hotlines have also been set up at overseas subsidiaries. In addition, a Minor Concern Corner has also been set up for worries that are not serious enough to warrant contacting a hotline. Each of these hotlines is widely available to Taisho Pharmaceutical Group employees as well as personnel including contract employees, part-time employees and temporary employees. Regardless of the situation, in accordance with the Company’s Internal Reporting Regulations, the privacy of hotline users is assured and related parties are obligated to maintain confidentiality.

Compliance Education

We hold annual workshops for all employees to deepen their understanding of compliance and understand that it is their own issue to address so that their practices reflect the importance of compliance. Since FY2020, a year dominated by the COVID-19 pandemic, we have established an environment for online training and added to our intranet a video about training which provides advice about the revision and enforcement of laws. Additionally, compliance workshops are held as part of company-wide basic training that is attended by about 3,000 employees from different divisions. We also provided stratified training to managers and people in higher-level positions including online workshops designed to enable employees to be aware of harassment and bullying in workplaces.
We also provide online compliance training to overseas subsidiaries.

In addition to these training programs, a portable compliance guide is distributed to all employees of Taisho Pharmaceutical with the goal of ensuring they are always aware of compliance and increase their understanding of compliance at workplaces. The TAISHO WAY and Global Compliance Guideline are published in all of the languages of our overseas subsidiaries to ensure our colleagues share our awareness of the importance of compliance both domestically and internationally. To date, these materials have been distributed to about 5,000 colleagues.

Required Considerations in Pharmaceutical Research and Development

Research involving human-derived samples is conducted only upon the fair and impartial deliberations of the Ethics Committee in accordance with internal regulations*1. These internal regulations were formulated after ample consideration of such issues as respect for human rights, commitment to safety, the protection of personal information and bioethics, pursuant to the Declaration of Helsinki and other guidelines.

We handle all compounds, radioisotopes, genetically modified organisms and infectious agents/pathogens with extreme care in order to protect the environment, safeguard biodiversity, and support people’s life and health based on internal regulations*2 that stipulate appropriate storage and management methods, pursuant to laws, regulations and other guidelines.

When conducting animal testing, plans are screened by the Animal Testing Committee in accordance with our internal regulations*3, which were formulated based on the animal welfare concepts of the three Rs*4 and meet the provisions of the Act on Welfare and Management of Animals and other regulations.

We have acquired certification of our animal facilities through the Japan Pharmaceutical Information Center and our pathogen and gene research facilities undergo inspections by the Certified NPO Biomedical Science Association to ensure appropriate operations.

  • *1. Ethical regulations regarding the use of human samples and information
  • *2. Safety management regulations for legally mandated substances, radiation injury prevention rules, genetic modification testing safety management rules, and safety management regulations for pathogens
  • *3. Refers to replacement (the use of alternatives to animal testing), reduction (reduction of the number of animals used) and refinement (reduction of pain inflicted)
  • *4. Regulations regarding animal testing